With zero management fees, a $5,000 minimum investment, and six years of consistent double-digit performance, Atlas Healthcare Fund is redefining what private healthcare investing looks like for accredited investors.
Since its launch in January 2020, Atlas Healthcare Fund has delivered six consecutive years of consistent, double-digit annual performance in the sector that never stops growing.
57%+
Annual Return (avg)
$193M
Assets Under Management
+1,721%
Cumulative Since 2020
3.31
Sharpe Ratio (1-Year)
What Is Atlas Healthcare Fund?
Atlas Healthcare Fund is a private healthcare equity fund managed by VST Capital a New York-based firm. The Fund invests exclusively in publicly traded healthcare companies — biopharmaceuticals, medical devices, managed care, life sciences tools, and digital health — using a concentrated, high-conviction approach built on deep clinical and scientific expertise.
Unlike most private funds that require six or seven-figure minimums and charge 2% management fees regardless of performance, Atlas Healthcare Fund was designed with complete alignment in mind. The minimum investment is just $5,000, there is no management fee of any kind, and the only compensation the fund takes is a tiered performance fee on net profits — meaning if you don’t profit, Atlas doesn’t earn a cent.
The fund currently manages $193 million in assets across 38 carefully selected healthcare positions, with holdings ranging from large-cap anchors like Eli Lilly and Johnson & Johnson to high-growth names like Summit Therapeutics and TransMedics Group.
Six Years of Consistent Returns — By the Numbers
Atlas Healthcare Fund has now completed its sixth full year of operation. The performance record is, by any objective measure, exceptional — and what makes it particularly unusual is not just the magnitude of returns, but their consistency across six full calendar years.
Year
Atlas Fund (Net)
XLV Benchmark
Alpha
Cumulative
2020
+56.88%
+13.4%
+43.5%
+56.9%
2021
+62.80%
+26.1%
+36.7%
+155.4%
2022
+57.41%
-2.4%
+59.8%
+302.0%
2023
+69.64%
+9.2%
+60.4%
+582.0%
2024
+57.73%
+2.5%
+55.2%
+975.7%
2025
+69.27%
+14.5%
+54.8%
+1,720.9%
To put the cumulative figure in perspective: $10,000 invested at inception in January 2020 would have grown to approximately $182,000 by the end of 2025 — net of all fees.
“Healthcare is the only industry that transcends every macro cycle. Wars, recessions, geopolitical crises — through every challenge in human history, one constant remains: people need medical care. We built Atlas to exploit that structural reality with the kind of specialist knowledge that generalist investors simply cannot replicate.”
— Dr. Sarah Morie, Founder & Chief Investment Officer
Why Healthcare? The Investment Case in Three Points
1. STRUCTURAL, NON-CYCLICAL DEMAND
Healthcare is the only major sector of the global economy where demand is fundamentally inelastic. People do not stop needing insulin when a recession hits. Hospitals do not stop purchasing surgical robots because interest rates rise. This structural characteristic — demand that exists independent of economic conditions — is the foundation of the healthcare sector’s long-term investment case and the reason Atlas Healthcare Fund has been able to deliver consistent returns through every macro environment since 2020.
The United States spends more than $4.5 trillion annually on healthcare, representing nearly 17.5% of GDP. Global healthcare spending is projected to grow at 5–7% annually through 2030, driven by aging demographics, chronic disease burden, and relentless innovation in therapeutics and medical technology.
2. THE DEMOGRAPHIC WAVE IS JUST BEGINNING
2.1 billion people worldwide will be over the age of 60 by 2050. In the United States, all baby boomers will be over 65 by 2030. This demographic wave creates persistent, growing demand for pharmaceuticals, medical devices, managed care services, and diagnostics that no policy change or market cycle can meaningfully interrupt. The healthcare sector does not need favourable macro conditions to grow — it needs only time.
3. A ONCE-IN-A-GENERATION INNOVATION CYCLE
We are living through the most prolific period of biomedical innovation in human history. The GLP-1 revolution has redefined the treatment of obesity, diabetes, and cardiovascular disease. CRISPR-based gene editing has moved from laboratory concept to approved therapy. Artificial intelligence is compressing drug discovery timelines from 12 years to as few as four. mRNA technology, validated by the COVID-19 pandemic, is now being applied to cancer, influenza, and rare diseases. Each of these platforms represents a multi-decade investment opportunity — and Atlas Healthcare Fund was built specifically to identify and invest in the best companies in each category.
The Specialist Advantage: Why Expertise Matters
The healthcare sector is one of the most complex and information-intensive in the global economy. Understanding FDA regulatory pathways, interpreting Phase III clinical trial data, evaluating patent expiry timelines, and modelling drug pricing dynamics across Medicare, Medicaid, and commercial insurance markets requires years of domain-specific expertise that generalist fund managers do not possess.
Atlas Healthcare Capital was purpose-built to exploit this informational advantage. The investment team includes:
Dr. Sarah Morie (CIO & Founder) — MD from Johns Hopkins, MBA from Wharton. Former portfolio manager at OrbiMed Advisors and Perceptive Advisors with 22 years in dedicated healthcare investing.
Hristian Rudman, CFA (Portfolio Manager) — BS Biomedical Engineering from MIT, MS Finance from NYU Stern. Previously Senior Analyst at Janus Henderson and Cowen’s healthcare equity desk.
Zero Management Fees — Complete Alignment
One of the most distinctive features of Atlas Healthcare Fund is its fee structure. At a time when the standard hedge fund model charges 2% management fees annually — regardless of whether the fund makes money — Atlas charges nothing unless investors profit.
0%
Management Fee
Sales Fee
Redemption Fee
Admin Charges
The only fee charged is a tiered performance fee on net profits. A high-water mark applies on a per-investor basis — meaning performance fees are only ever charged on new profits above each investor’s prior peak account value. In any period where the fund does not generate a net profit, no fee of any kind is charged.
Who Can Invest in Atlas Healthcare Fund?
Atlas Healthcare Fund is available to accredited investors as defined under SEC Regulation D. This includes individuals with a net worth exceeding $1 million (excluding primary residence) or annual income above $200,000 ($300,000 joint) for two consecutive years, as well as qualifying entities, trusts, and retirement accounts.
The fund accepts the following account types:
Individual accounts
Joint accounts
Business and entity accounts
Trust accounts
IRA and retirement accounts
The minimum investment is $5,000 — significantly lower than most private funds, which typically require $100,000 or more. A 90-day lock-up period applies from the date of each investment, after which quarterly redemptions are available with 90 days’ written notice.
How to Open an Account
Opening an account with VST Capital is straightforward. Investors can apply in two ways:
Online — Visit www.vstcapital.com to complete the digital account application in approximately 10–15 minutes.
PDF Application — Download the account application form, complete it, and return it by email to [email protected] or by fax.
Applications are reviewed within 1–2 business days. Upon approval, investors receive wire transfer instructions and access to the investor portal, where account balances, statements, and portfolio reports are available at any time.
Disclaimer: This press release may contain forward-looking statements regarding the future performance, investment strategy, financial results, market opportunities, and business plans of VST Capital and the Atlas Healthcare Fund. These statements are based on current expectations and assumptions and are subject to risks, uncertainties, and changes in market conditions. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results and should not be relied upon as a guarantee of future performance. Nothing in this press release constitutes investment, legal, tax, or financial advice, or an offer to buy or sell any securities. Investments involve risk, including the possible loss of principal. Investors should conduct their own due diligence and consult qualified financial advisors before making investment decisions.
Media ContactCompany Name: VST CapitalContact Person: Charles BroersmaEmail: Send EmailCountry: United StatesWebsite: https://www.cazbah.net/
